Comparison of Activities of Broad-Spectrum β-Lactam Compounds against 1,128 Gram-Positive Cocci Recently Isolated in Cancer Treatment Centers | Zendy

Daniel J. Diekema | Zendy; Stacy L. Coffman | Zendy; Steven A. Marshall | Zendy; Mondell L. Beach | Zendy; Kenneth V. I. Rolston | Zendy; Ronald N. Jones | Zendy

Open Access

Comparison of Activities of Broad-Spectrum β-Lactam Compounds against 1,128 Gram-Positive Cocci Recently Isolated in Cancer Treatment Centers

Author(s) -

Daniel J. Diekema,

Stacy L. Coffman,

Steven A. Marshall,

Mondell L. Beach,

Kenneth V. I. Rolston,

Ronald N. Jones

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.4.940

Subject(s) - cefepime , ceftazidime , imipenem , microbiology and biotechnology , enterococcus , vancomycin , ceftriaxone , empiric therapy , antimicrobial , medicine , antibiotics , biology , staphylococcus aureus , bacteria , antibiotic resistance , pseudomonas aeruginosa , genetics

We report the in vitro activities of broad-spectrum β-lactam antimicrobials tested against 1,128 gram-positive pathogens recently isolated from cancer patients. Cefepime and imipenem were more active than ceftazidime and ceftriaxone against these organisms. Only vancomycin demonstrated reliable activity against oxacillin-resistant staphylococci,Enterococcus spp., andCorynebacterium spp. The spectrum of gram-positive organisms against which cefepime and imipenem have activity provides an advantage over ceftazidime as empiric therapy for cancer patients, potentially reducing the need for the empiric addition of glycopeptides.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research